Alzheimer's disease research points to Arc protein risk

Alzheimer's disease researchers have linked Arc, a neuron-signaling protein, to toxic Tau spread in mice and a possible treatment target.

The work, published in Cell, gives scientists a sharper view of how damage may move from one brain cell to another as symptoms worsen. Jason Shepherd, PhD, professor of neurobiology at University of Utah Health and senior author of the study, said the finding identifies a possible intervention point in disease progression.

Arc enters the Tau pathway

Arc normally supports communication between neurons, a basic function needed for brain signaling. The researchers found that the same system may be used by toxic Tau, the protein associated with damaging tangles in Alzheimer's disease.

Arc can package itself inside extracellular vesicles, small membrane-wrapped carriers that move signals between neurons. In the mouse study, Tau appeared to attach to Arc inside these vesicles, giving the toxic protein a route from affected cells into healthier ones.

Every neuron contains Tau, but the protein becomes harmful when it forms sticky clumps that disrupt internal transport and injure the cell. Mitali Tyagi, PhD, first author of the study and a postdoctoral research associate at Washington University in St. Louis, described the larger tangles as "glue monsters."

"They glue together and block transportation within the neuron," Tyagi said. "But they can break down into smaller glue monsters, called Tau seeds, which can then get transferred to a new neuron. And once this Tau seed comes into contact with healthy Tau, it is able to corrupt it. So, the pathology starts all over again in a healthy neuron."

Mouse model shows Arc dependence

The team compared Alzheimer's mouse models that had Arc with models in which the protein was removed. In brain tissue from the disease model, researchers found extracellular vesicles carrying both Arc and sticky Tau.

Those vesicles were able to enter healthy cells and trigger new Tau tangles, according to the study. When Arc was absent, the vesicles contained very little Tau, and the spread to nearby brain cells was sharply reduced.

"When we removed Arc, we saw that the transfer of Tau was severely, severely reduced," Tyagi said. "It was almost gone."

The finding narrows the mechanism, but it does not establish that blocking Arc would slow Alzheimer's disease in people. The source study was conducted in mice, so the central uncertainty is whether the same Arc-dependent process operates in human brain tissue at a scale that would matter clinically.

Treatment question moves upstream

The study points toward a different treatment logic: stop toxic Tau from reaching new cells rather than trying to clear all Tau from the brain. That distinction matters because Tau also has normal cellular roles, while disease spread may depend on specific transfer routes.

If further research confirms the mechanism in humans, drug developers could look for ways to interrupt Tau's loading into Arc-containing vesicles or block the vesicles from entering healthy neurons. For University of Utah Health's team, the company-level equivalent is institutional research momentum: the finding could support new grants, collaborations or translational programs built around Tau transport.

The wider Alzheimer's research field would face a more targeted question. Rather than treating Tau as a single toxic mass, researchers could separate the biology of Tau formation from the biology of Tau movement, creating a narrower set of drug targets.

Several risks remain. Arc is tied to normal neuron communication, so any therapy aimed at this pathway would need to avoid damaging the signaling it is meant to preserve.

The next tests are likely to focus on human relevance, safety and whether the Arc-Tau interaction can be interrupted without broad effects on brain function. If the result holds across models, the macro effect for health systems would be longer-term rather than immediate: slowing progression could reduce care burden, while failure to translate would leave the industry searching for other ways to contain Tau spread.